Phase 3 Clinical Study of a New Cancer Immunotherapy Extends Survival in Patients with Refractory Melanoma

Published June 8, 2010

Phase 3 Clinical Study of a New Cancer Immunotherapy Extends Survival in Patients with Refractory Melanoma
First treatment ever proven in a randomized trial to extend life for patients whose melanomas are unresponsive to existing cancer therapies.